Nihon Koden Acquires U.S. Software Developer Neurotronics
This article was originally published in PharmAsia News
Executive Summary
Nihon Koden announced Dec. 26 the company will acquire 100 percent of shares of U.S. software developing company Neurotronics by Dec. 31. Nihon Koden's move is to further strengthen its sleep respiratory business, which the company hopes to reach ¥1 billion in sales by March 2009 and ¥2 billion by March 2011. The company will utilize sleep brain wave analysis technology developed by Neurotronics and develop products to treat sleep apnea syndrome. Based in Gainesville, Florida, Neurotronics has 18 employees. Nihon Koden estimates that Polysomnography all-night sleep polygraph testing that uses brain wave analysis software to diagnose SAS will spread rapidly in the future. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.